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Recessive Dystrophic Epidermolysis 
Bullosa–Associated Squamous-Cell 
Carcinoma: An Enigmatic Entity with 
Complex Pathogenesis
Ulrich Rodeck1 and Jouni Uitto1
Expression of either collagen VII or the noncollagenous (NC1) fragment derived 
from it has been suggested to be indispensable for the development of squamous-
cell carcinomas (SCCs) in patients affected by recessive dystrophic epidermoly-
sis bullosa (RDEB). This view is challenged here by the observation that SCCs do 
develop in RDEB patients lacking expression of collagen VII altogether. The aggres-
sive behavior of RDEB-associated SCCs remains unexplained.
Journal of Investigative Dermatology (2007) 127, 2295–2296. doi:10.1038/sj.jid.5700939
The term epidermolysis bullosa (EB) 
represents a heterogeneous group of 
mechanobullous disorders characterized 
by skin fragility and blister formation. In 
addition to the skin, a number of other 
specialized epithelia, including the oral 
mucous membranes as well as those of 
the respiratory, vesicourinary, and gas-
trointestinal tract, can be affected (Fine 
et al., 1999). In milder forms of EB, blis-
ters may be confined to limited areas of 
the skin, primarily the hands and feet. In 
contrast, in the most severe forms of EB, 
minimal trauma can result in widespread 
blistering and cutaneous erosions that 
heal slowly, if at all. The clinical course 
of the recessive dystrophic form of EB 
(RDEB, the Hallopeau–Siemens type; 
OMIM#226600) is unrelenting, and the 
affected patients develop severe mutilat-
ing scarring and are at high risk of devel-
oping squamous-cell carcinomas (SCCs) 
of the skin. Unlike sporadic SCCs in the 
general population, the RDEB-associ-
ated SCCs readily metastasize and have 
emerged as a prevalent life-threatening 
complication in these patients (Fine et 
al., 1999).
The cutaneous fragility in RDEB is 
caused by mutations in the COL7A1 
gene, which encodes type VII collagen, a 
structural component of anchoring fibrils 
at the cutaneous basement membrane 
zone (Varki et al., 2007). Wild-type colla-
gen VII contributes to the structural integ-
rity of the basement membrane zone by 
tethering the lamina densa of the dermo-
epidermal basement membrane to the 
underlying papillary dermis (Shimizu et 
al., 1997). A wide spectrum of COL7A1 
mutations that affect either collagen VII 
protein production or fibrillar assem-
bly have been linked to DEB. In RDEB 
patients, premature STOP codons are 
frequently observed, predicting expres-
sion of truncated collagen VII, including 
the noncollagenous 1 (NC1) domain, 
but lacking C-terminal sequences nec-
essary for collagen VII assembly. The 
molecular genetic hallmark of the most 
severe RDEB is STOP codon mutations 
in both alleles, spanning the entire 
length of the collagen VII polypeptide 
(Varki et al., 2007).
Ortiz-Urda and colleagues (2005) 
recently demonstrated that expression 
of the NC1 fragment was required for 
malignant transformation of a series 
of keratinocytes isolated from RDEB 
patients. In addition, they observed that 
expression of either full-length collagen 
VII or the NC1 fragment was necessary 
for tumorigenic conversion of normal 
keratinocytes from non-RDEB individu-
als. Pourreyron et al. (2007, this issue) 
revisited the requirement of collagen 
VII expression for SCC development in 
another series of SCC cell lines isolated 
from RDEB patients. They demonstrate 
that 2 of 11 patients investigated devel-
oped SCC in the absence of collagen VII 
or NC1 expression and conclude that, in 
RDEB patients, expression of collagen VII 
fragments is not a necessary requirement 
for SCC development. In support of this 
notion, we have identified in the DebRA 
Molecular Diagnostics Laboratory muta-
tion database seven RDEB patients who 
were compound heterozygotes with 
two COL7A1 STOP codon mutations in 
trans upstream from the NC1/C7 junc-
tion (Varki et al., 2007). These patients 
are predicted not to express NC1, yet 
two of three, who were over 30 years 
of age, have developed aggressive SCCs 
(J. Uitto, unpublished observations).
Can these seemingly contradictory 
results be reconciled? The answer may 
lie in the use of distinct experimental 
systems that were employed to assess 
malignant transformation. Ortiz-Urda et 
al. (2005) based their study on the use of 
an experimental model system to assess 
the tumorigenic potential of normal kera-
tinocytes. To achieve tumorigenicity in 
immunodeficient mice, they retrovirally 
transduced normal keratinocytes with 
oncogenic Ras (Ha-Ras-V12) and the 
NF-κB inhibitor IκBα. Thus, expression 
of collagen VII appears to be an absolute 
requirement for tumor formation driven 
by Ha-Ras, leaving open the question of 
whether this observation can be general-
ized to RDEB patients. Pourreyron et al. 
(2007) resolve this question by demon-
strating that expression of collagen VII or 
fragments thereof is not strictly required 
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for SCC development in patients. Clearly, 
their findings must be confirmed in a 
larger cohort of RDEB patients afflicted 
with SCCs. However, their work high-
lights the importance of molecular epi-
demiology in patients to ascertain the 
relevancy of findings in experimental 
models of skin tumor development.
Of course, it is possible that the 
requirement of NC1 expression for SCC 
development is restricted to a subset of 
RDEB patients in which Ha-Ras muta-
tions occur. In sporadic SCCs Ras muta-
tions are infrequent and typically occur 
late in tumor progression (Campbell 
et al., 1993; Clark et al., 1993). 
Unfortunately, the activation state of Ha-
Ras in RDEB-associated SCCs is current-
ly unknown. If a high frequency of Ras 
mutations should be prevalent in RDEB-
associated SCCs, it would be of interest 
to determine whether the tumors formed 
in the absence of collagen VII expression 
exhibit deregulated signaling pathways 
normally dependent on the presence of 
either collagen VII or the NC1 domain 
(Rodeck et al., 2007). Regardless of the 
results of future efforts to resolve these 
issues, expression of the NC1 domain 
of collagen VII alone is not likely to pro-
vide a reliable diagnostic tool to iden-
tify patients at risk of SCC development. 
Instead, collagen VII joins a long list of 
extracellular matrix components that 
have been implicated in SCC develop-
ment at the microenvironment of the 
tumor–host interface, including collagen 
IV, collagen I, fibronectin, and laminin 
332 (formerly laminin 5) (Abelev and 
Lazarevich, 2006; Marinkovich, 2007). 
Much like these, collagen VII may act 
as a “modifier” of the transformed state 
by enhancing the malignant potential 
of initiated keratinocytes. Yet none of 
these extracellular matrix components is 
likely to be an absolute requirement for 
tumor progression.
RDEB, more so than less aggressive 
forms of EB, is characterized by chronic 
wound healing and excessive scar for-
mation that last decades before SCCs are 
manifest. An interesting parallel to SCCs 
arising in continuously remodeling scar 
tissue is Marjolin’s ulcers—SCCs that 
typically arise in burn scars many years 
after the initial scarring event (Phillips et 
al., 1998). Interestingly, these SCCs are 
also very aggressive and invasive, much 
like RDEB-associated SCCs. These paral-
lels raise the question of whether, regard-
less of collagen VII/NC1 expression sta-
tus, chronic wound healing represents 
the driving force for the development of 
highly malignant SCCs in both the gen-
eral population and RDEB patients.
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Genital and Nongenital Nonmelanoma 
Skin Cancer: More Epidemiological 
Studies Are Needed
Andreas Stang1
Although black men in the United States have a lower mortality of nongenital 
nonmelanoma skin cancer (NMSC) than white men, they have a higher mortal-
ity of genital NMSC than white men. Mortality of NMSC has declined over time. 
Ethnicity-specific incidence and survival analyses of NMSC can be used to deter-
mine to what degree earlier detection and/or more efficient therapies have con-
tributed to these observations.
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The burden of nonmelanoma skin cancer 
(NMSC) can be described by a variety of 
measures, including mortality. Although 
death among people with NMSC is the 
exception rather than the rule, detailed 
analyses of routinely collected mortal-
ity data provide important insights into 
the burden of disease. For example, 
although the age-standardized mortality 
rates of NMSC decreased in the territory 
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